3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
10
Lymphoid
2
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
22
Melanoma
6
Histiocytoma, Malignant Fibrous
6
Gastrointestinal Stromal Tumors
5
Osteosarcoma
4
Neoplasm Metastasis
4
Gliosarcoma
4
Neuroblastoma
3
Hemangiosarcoma
3
Chordoma
3
Bone Neoplasms
3
Wilms Tumor
2
Triple Negative Breast Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Lymphoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Liposarcoma
2
Head and Neck Neoplasms
2
Glioblastoma
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Bile Duct Neoplasms
2
Interventions
Gemcitabine
5
Cisplatin
5
Oxaliplatin
4
pembrolizumab
3
Irinotecan
3
Carboplatin
3
Specimen Handling
2
Radiosurgery
2
Psychiatric Rehabilitation
2
Observation
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Floxuridine
2
Erlotinib Hydrochloride
2
Cyclophosphamide
2
Cetuximab
2
Bortezomib
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tislelizumab
1
spartalizumab
1
sodium thiosulfate
1
selpercatinib
1
rucaparib
1
repotrectinib
1
pidilizumab
1
pazopanib
1
p53 peptide 264-272, human
1
motexafin lutetium
1
montanide ISA 51
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Ipilimumab
×
Sarcoma
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts